Burning Rock Secures USPTO Patent, Q4 Revenue Steady at RMB126.3M
Burning Rock’s ELSA-seq ultrasensitive detection technology secured USPTO patent US 12460202 B2 and its OncoScreen BCMatch Tissue Kit entered priority review at China’s NMPA. In Q4 2025, revenue held steady at RMB126.3M while gross margin rose to 78.0% and net loss shrank to RMB15.4M from RMB81.3M a year earlier.
1. Patent and Regulatory Updates
Burning Rock secured USPTO patent US12460202 B2 for its ELSA-seq ultrasensitive detection technology and its OncoScreen BCMatch Tissue Kit entered priority review at China’s NMPA, marking key intellectual property and regulatory milestones.
2. Q4 2025 Revenue and Profitability
Revenue for the three months ended December 31, 2025 reached RMB126.3 million, flat year-over-year, while gross profit climbed 10.2% to RMB98.6 million, boosting gross margin to 78.0% from 71.0% a year earlier.
3. Segment Performance Trends
Central laboratory revenues rose 12.1% to RMB44.0 million and in-hospital revenue grew 17.3% to RMB51.0 million, offset by a 27.7% drop to RMB31.3 million in pharma R&D services due to timing of project engagements.
4. Cost Controls and Net Loss Reduction
Operating expenses fell 35.5% to RMB110.6 million on headcount cuts and budget controls, contributing to a net loss of RMB15.4 million versus RMB81.3 million in Q4 2024.